---
title: "Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295410289.md"
description: "Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. (EVMN) with a $22 price target. This follows a recent Buy from Morgan Stanley, while William Blair previously held a Hold rating. The coverage highlights strong analyst performance metrics for Clark-Gartner in the healthcare sector."
datetime: "2026-08-10T12:45:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295410289.md)
  - [en](https://longbridge.com/en/news/295410289.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295410289.md)
generator: "portal-rs"
---

# Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Evommune, Inc. today and set a price target of $22.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Clark-Gartner covers the Healthcare sector, focusing on stocks such as Dyne Therapeutics, AbbVie, and Sarepta Therapeutics. According to TipRanks, Clark-Gartner has an average return of 43.7% and a 66.08% success rate on recommended stocks. 

In addition to Evercore ISI, Evommune, Inc. also received a Buy from Morgan Stanley’s Judah Frommer in a report issued today. However, on August 7, William Blair maintained a Hold rating on Evommune, Inc. (NYSE: EVMN).

### Related Stocks

- [EVMN.US](https://longbridge.com/en/quote/EVMN.US.md)
- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [09:01 ETHealthcare Is Moving Into the Home. Home Accessibility Now Has a Validated Score.](https://longbridge.com/en/news/297656740.md)
- [SoundHound AI (SOUN) On Healthcare Deal Momentum And The Case For A Higher Valuation](https://longbridge.com/en/news/297694466.md)
- [Morgans Remains a Buy on EchoIQ Limited (EIQ)](https://longbridge.com/en/news/297720502.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)
- [TPG’s Asia OneHealthcare said to confidentially file for US$2.5 billion IPO](https://longbridge.com/en/news/297874967.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**